Why the study?
Does continuous glucagon infusion improve clinical outcomes in patients with cardiac failure?
Does continuous glucagon infusion improve clinical outcomes in patients with cardiac failure?
Continuous glucagon infusion may provide clinical improvement in chronic refractory congestive failure, but is associated with side effects including hypokalemia-induced ventricular fibrillation and elevated blood urea nitrogen.
Answers are grounded in this paper and cite their sources.
May support glucagon use in select chronic HF cases; hypothesis-generating and should not change practice without RCTs.
Twelve courses of continuous glucagon infusion were administered to ten patients at rates of 0.5 to 16 mg/hr for periods of 5 to 166 hours. Six infusions were given for chronic refractory congestive failure, three for postperfusion low flow, and three for cardiogenic shock. Improvement was noted in nine of ten patients including all with chronic congestive failure. Half of the latter group were discharged whereas only one of four patients with acute myocardial impairment survived. Side effects were frequent but mild. One patient, however, had three episodes of ventricular fibrillation associated with hypokalemia. Most patients developed an as yet unexplained increase in blood urea nitrogen. This is the third favorable report of seven such studies involving chronic congestive failure and indicates the necessity for further observations in such patients and in those with chronic obstructive lung disease with cor pulmonale.
No takes yet. Share an insight, caveat, or question.
GERALD C. TIMMIS (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: